- Home
- KNSA vs NAVI Comparison
KNSA vs NAVI Comparison
Compare KNSA & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- NAVI
- Stock Information
- Founded
- KNSA 2015
- NAVI 1973
- Country
- KNSA United Kingdom
- NAVI United States
- Employees
- KNSA N/A
- NAVI N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- NAVI Investment Bankers/Brokers/Service
- Sector
- KNSA Health Care
- NAVI Finance
- Exchange
- KNSA Nasdaq
- NAVI Nasdaq
- Market Cap
- KNSA 2.6B
- NAVI 1.3B
- IPO Year
- KNSA 2018
- NAVI N/A
- Fundamental
- Price
- KNSA $37.10
- NAVI $12.87
- Analyst Decision
- KNSA Strong Buy
- NAVI Hold
- Analyst Count
- KNSA 6
- NAVI 8
- Target Price
- KNSA $40.83
- NAVI $14.19
- AVG Volume (30 Days)
- KNSA 431.3K
- NAVI 750.1K
- Earning Date
- KNSA 10-28-2025
- NAVI 10-29-2025
- Dividend Yield
- KNSA N/A
- NAVI 4.97%
- EPS Growth
- KNSA N/A
- NAVI N/A
- EPS
- KNSA 0.07
- NAVI 0.31
- Revenue
- KNSA $529,332,000.00
- NAVI $584,000,000.00
- Revenue This Year
- KNSA $37.21
- NAVI N/A
- Revenue Next Year
- KNSA $11.99
- NAVI N/A
- P/E Ratio
- KNSA $573.99
- NAVI $41.66
- Revenue Growth
- KNSA 56.18
- NAVI N/A
- 52 Week Low
- KNSA $17.82
- NAVI $10.53
- 52 Week High
- KNSA $37.34
- NAVI $16.44
- Technical
- Relative Strength Index (RSI)
- KNSA 73.54
- NAVI 39.09
- Support Level
- KNSA $35.72
- NAVI $12.95
- Resistance Level
- KNSA $37.25
- NAVI $13.84
- Average True Range (ATR)
- KNSA 0.95
- NAVI 0.37
- MACD
- KNSA 0.14
- NAVI -0.05
- Stochastic Oscillator
- KNSA 94.82
- NAVI 0.99
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.